An open-label, pilot study evaluating the safety and antidepressant effects of rellidep in major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 34, Issue 2, 2014, Pages 230-233

  Sadavoy, Joel ^a,b   Bain, Jerald ^b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d United Paragon Associates   (Canada)

Author keywords

Antidepressant; Biological tissue isolate; Depression; Glutamate antagonist; NK2 antagonist; Rellidep

Indexed keywords

ANTIDEPRESSANT AGENT; LORAZEPAM; RELLIDEP; UNCLASSIFIED DRUG;

ADULT; AGED; ARIZONA SEXUAL EXPERIENCE SCALE; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFECT; DRUG SAFETY; FEMALE; HAMILTON RATING SCALE FOR ANXIETY; HAMILTON SCALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR DEPRESSION; MALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; SHORT FORM 36; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANIMALS; ANTIDEPRESSIVE AGENTS; CHICK EMBRYO; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; TISSUE EXTRACTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896389855     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000068     Document Type: Article

References (32)

1. National Survey on Drug Use and Health: National Findings. Revisions as of September 8, 2005. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration Office of Applied Studies. Available at: http://www.samhsa.gov/data/nsduh/2k4nsduh/2k4results/2k4results.pdf. Accessed July 7, 2013.
2. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358(1): 55.
3. Kennedy S, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16: 93-100.
4. Palucha A, Pilc A. Metabotropic glutamate receptor ligands as possible anxioytic and antidepressant drugs. Pharmacol Ther. 2007;115: 116-147.
5. Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci. 2003;100: 3250-3272.
6. Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets. 2007;6: 101-115.
7. Toro CT, Hallak JE, Dunham JS, et al. The NRI N-methyl-D-aspartate subunit and brain-derived neurotrophic factor in temporal lobe epilepsy hippocampus: a comparison of patients with and without coexisting psychiatric symptoms. Epilepsia. 2007;48: 2352-2856.
8. Kendler KS, Walters EE, Kessler RC. The prediction of length of major depressive episodes: results from an epidemiological sample of female twins. Psychol Med. 1997;27: 107-117.
9. McLeod JD, Kessler RC, Landis KR. Recovery from major depressive episodes in a community sample of married men and women. J Abnorm Psychol. 1992;101: 277-286.
10. Patten S. The duration of major depressive disorders in the Canadian general population. Chronic Dis Canada. 2001;22: 1.
11. Treatment of chronic depression [editorial]. N Engl J Med. 2000;342: 1518-1520.
12. Eaton W, Shao H, Nestadt G, et al. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry. 2008;65(5): 513-520.
13. Kleshcheva RP. An embryonic tissue xenograft of neocortes in old rats. Arkh Anat Gistol Embriol. 1991;100(3): 16-19.
14. Akimova IM, Gurchin FA, Meliucheva LA, et al. Dynamics of Mental disorders after extracerebral implantation of embryonic nervous tissue in epilepsy [in Russian]. Zh Nevrol Psikiatr Im S SKorsakova. 2000;100(11): 38-41.
15. Eskland B, Thom E, Svedsen KOB. Sexual desire in men: effects of oral ingestion of a product derived from fertilized eggs. J Intern Med Res. 1997;25: 62-70.
16. Mihǎescu G, Olinescu R, Oancea F. Significant modification of lipid metabolism in aged persons following the treatment with a nutritive supplement containing embryonary peptidesVpreliminary results. Rom J Intern Med. 2005;43(1-2): 133-139.
17. Solberg E. The effects of powdered fertilized eggs on depression. J Med Food. 2011;14(7-8): 870-875.
18. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychiatry. 1967;6: 278-296.
19. Guy W. ECDEU Assessment Manual for PsychopharmacologyVRevised (DHEW Publication ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976: 218-222.
20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134: 382-389.
21. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30: 473-483.
22. Beck AT, Ward CH, Mock J, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4: 561-571.
23. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32: 50.
24. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26: 25-40.
25. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;76: 1-100.
26. Maeng S, Zarate CA Jr. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. J Curr Psych Rep. 2007;9: 467-474.
27. Kudoh A, Takahira Y, Katagai H, et al. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg. 2002: 95: 114-118.
28. McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr. 2008;13: 501-510.
29. Louis C, Stemmelin J, Boulay D, et al. Additional evidence for anxiolytic-and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol Biochem Behav. 2008;89: 36-45.
30. Micale V, Tamburella A, Leggio GM, et al. Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions. Pharmacol Biochem Behav. 2008;90: 463-469.
31. Salomé N, Stemmelin J, Cohen C, et al. Selective blockade of NK2 or NK3 receptors produces anxiolytic-and antidepressant-like effects in gerbils. Pharmacol Biochem Behav. 2006;83: 533-539.
32. Teixeira RM, Santos AR, Ribeiro SJ, et al. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Euro J Pharmacol. 1996;311: 7-14.